First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Reports of ChAdOx1 vaccine–associated thrombocytopenia and vascular adverse events have led to some countries restricting its use. Using a national prospective cohort, we estimated associations between exposure to first-dose ChAdOx1 or BNT162b2 vaccination and hematological and vascular adverse even...

Descripción completa

Detalles Bibliográficos
Autores principales: Simpson, C. R., Shi, T., Vasileiou, E., Katikireddi, S. V., Kerr, S., Moore, E., McCowan, C., Agrawal, U., Shah, S. A., Ritchie, L. D., Murray, J., Pan, J., Bradley, D. T., Stock, S. J., Wood, R., Chuter, A., Beggs, J., Stagg, H. R., Joy, M., Tsang, R. S. M., de Lusignan, S., Hobbs, R., Lyons, R. A., Torabi, F., Bedston, S., O’Leary, M., Akbari, A., McMenamin, J., Robertson, C., Sheikh, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282499/
https://www.ncbi.nlm.nih.gov/pubmed/34108714
http://dx.doi.org/10.1038/s41591-021-01408-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282499/
https://www.ncbi.nlm.nih.gov/pubmed/34108714
http://dx.doi.org/10.1038/s41591-021-01408-4

Ejemplares similares